春立医疗(688236) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥221,850,180.79, representing a decrease of 9.95% compared to the same period last year[9]. - The net profit attributable to shareholders for Q1 2024 was ¥55,199,616.28, down by 1.18% year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥48,882,462.10, a decrease of 1.46% compared to the previous year[9]. - The total comprehensive income attributable to the parent company was CNY 55,199,616.28, a decrease from CNY 55,861,404.05 in the previous period[23]. - The company reported a decrease in comprehensive income total to CNY 55,107,063.21 from CNY 55,861,404.05[23]. - Basic and diluted earnings per share were both CNY 0.14, down from CNY 0.15 in the previous period[23]. Cash Flow - The net cash flow from operating activities was negative at ¥129,613,339.07, indicating a significant cash outflow[9]. - The cash flow from operating activities showed a significant impact from the changes in cash and cash equivalents[25]. - In Q1 2024, the company reported cash inflows from operating activities totaling CNY 217,425,731.31, compared to CNY 212,802,558.95 in Q1 2023, reflecting a slight increase of approximately 1.5%[42]. - The net cash outflow from operating activities was CNY -129,613,339.07, which is a decrease in outflow compared to CNY -120,197,574.28 in the same period last year[43]. - The company achieved cash inflows from investment activities of CNY 837,229,065.92, up from CNY 771,181,481.64 in Q1 2023, indicating an increase of about 8.6%[43]. - The net cash flow from investment activities was CNY 83,728,306.55, significantly higher than CNY 1,551,246.27 in Q1 2023[43]. - The company reported a significant increase in cash received from investment recoveries, totaling CNY 831,300,000.00 in Q1 2024, compared to CNY 765,000,000.00 in Q1 2023[43]. Assets and Liabilities - The total assets at the end of Q1 2024 were ¥3,542,662,190.69, a decrease of 2.93% from the end of the previous year[12]. - Total current assets as of March 31, 2024, were CNY 2,899,501,388.96, down from CNY 3,005,359,817.46 at the end of 2023, representing a decrease of approximately 3.5%[45]. - The company's cash and cash equivalents decreased to CNY 1,220,478,879.78 from CNY 1,266,367,522.67, a decline of about 3.6%[45]. - The total liabilities decreased from CNY 676,672,835.51 to CNY 514,691,217.05, indicating a reduction of approximately 23.9%[42]. - Total liabilities amounted to CNY 608,374,106.90, down from CNY 770,325,491.93 in the previous period[47]. - The company's intangible assets slightly decreased from CNY 136,270,839.38 to CNY 133,622,900.88, a decline of about 2.0%[42]. - Minority interests decreased to CNY 1,621,614.17 from CNY 1,768,579.61, indicating a reduction in minority shareholder equity[47]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,133[14]. - The largest shareholder, Shi Chunbao, holds 29.94% of the shares, totaling 114,840,685 shares[14]. - The total number of ordinary shareholders was 6,133, with 6,116 holding A shares and 17 holding H shares[34]. - The top ten shareholders included HKSCC NOMINEES LIMITED with 95,125,175 shares, representing 24.80% of total shares[30]. Research and Development - Research and development expenses totaled ¥34,991,868.71, which accounted for 15.77% of operating revenue, an increase of 2.26 percentage points year-on-year[12]. Other Financial Metrics - The weighted average return on equity was 1.90%, a decrease of 0.13 percentage points compared to the previous year[12]. - The basic and diluted earnings per share were both ¥0.14, reflecting a decline of 6.67% year-on-year[12]. - The company's retained earnings increased to CNY 1,322,712,624.53 from CNY 1,267,513,008.25, reflecting a growth of approximately 4.36%[47]. - Non-current liabilities totaled CNY 93,682,889.85, slightly up from CNY 93,652,656.42[47]. - The company reported no net profit from the merged entity prior to the merger, consistent with the previous period[50]. - The company has not adopted new accounting standards for the current year, indicating stability in financial reporting practices[53].